KRN key partner in FIRSTx milestone achievement!
The FIRSTx trial has successfully reached its enrollment goal and the KRN coordinating center was a critical partner.
Enrollment completion in this FSGS trial is a significant milestone. KRN and Complexa, Inc, the trial sponsor, implemented a unique approach to recruitment and site partnerships leading to this achievement. Read more...
FIRSTx is a phase 2 study testing the safety and effectiveness of investigational drug called CXA-10 designed to treat FSGS without steroids.The study is taking place at approximately 23 centers across the United States. The results of the initial 90-day dosing treatment phase are expected in the second half of 2020 with an open-label extension continuing into 2021.
For more information please visit: